GHRS logo

GHRS GH Research PLC

NASDAQ Global Market · Biotechnology · Healthcare

$17.53
-1.03 (-5.55%)

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate …

Market Cap: $1.20Bwww.ghres.com

Price

No data yet.

Social Signal Score

49
5d
50
1 mentions
—
30d
47
3 mentions
—
60d
51
4 mentions
—
90d
50
5 mentions
—
news: 5

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 0Sell 0Strong Sell 0
Avg price target$45.33+158.6%
Low $38Median $42High $65
Current Consensus

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-0.84
$-0.88–$-0.78
5 analysts
FY2026
$-0.98
$-1.28–$-0.81
7 analysts
FY2027
$-1.53
$-2.11–$-1.29
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Velichka Valcheva
Sector
Healthcare
Industry
Biotechnology
Employees
73
Beta
1.32
Country
IE
Piotroski score
2 / 9 (Weak)
Altman Z-score
66.08
www.ghres.com